Cambridge Consultants reveals details of a revolutionary new inhaler developed for mass vaccination against chronic diseases and global pandemics, such as avian flu. The new inhaler, called 'Conix One' delivers the performance expected of high-end inhalers at a lower cost than a syringe. In addition to these key performance and price achievements, the inhaler is extremely simple to use and is safe for front-line health workers.
This breakthrough product is expected to bring the ease and convenience of inhaled drug delivery to global scale initiatives where the key is to treat as many people as effectively, quickly and as economically as possible.
Today, large-scale vaccinations are typically delivered via syringe, but for many chronic diseases inhalation offers the optimum delivery mechanism. The inhaler is comfortable for the patient to administer and easy to use - the patient simply folds the device shut, inhales and then discards. This also eliminates the significant risk of needle stick injuries and infection, which in countries where diseases such as HIV are prevalent, poses a real threat to the lives and wellbeing of health workers.
This inhaler will fundamentally change the way we treat many diseases on a global scale.
The new inhaler is based around a novel 'reverse flow cyclone' and contains no moving parts or propellants - in fact the inhaler is made from a single piece of plastic and costs just four cents to manufacture in high volume (5M per annum). Although manufacturing the new inhaler is similar in cost to that of the syringe, there are significant savings to be made as syringes are more expensive to distribute (drug in liquid form typically requires refrigeration) and they require skill and training to use. The Conix One inhaler uses a simple foil seal to protect the formulation from moisture and many patients can use their devices at the same time, making rollout far faster.
The unique swirling action within the patented cyclone provides an extremely effective deagglomeration process, enabling a large percentage of drug to be delivered efficiently into the lung. This action also overcomes the problem that many inhalers have, where the drug is released within just a fraction of a second - before the patient has had time to reach their optimal inhalation rate. The cyclone chamber releases a steady flow of drug over two seconds, enabling better use of a patient's lung power